Chondrocyte disc regeneration therapy - Isto Biologics

Drug Profile

Chondrocyte disc regeneration therapy - Isto Biologics

Alternative Names: Allogenic juvenile chondrocytes; NuQu; NuQu® Spine

Latest Information Update: 14 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ISTO Technologies
  • Developer Isto Biologics
  • Class Analgesics; Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 01 Sep 2016 ISTO Technologies terminates a phase II trial in Intervertebral-disc-degeneration in USA (Parenteral) due to change in clinical strategy (NCT01771471)
  • 09 Feb 2016 Phase-II development is ongoing in USA
  • 07 Oct 2013 ISTO Technologies completes enrolment in its phase II trial for Intervertebral-disc-degeneration in USA (NCT01771471,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top